Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-07
2006-02-07
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S269000, C424S649000
Reexamination Certificate
active
06995165
ABSTRACT:
Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.
REFERENCES:
patent: 5326764 (1994-07-01), Milstone et al.
Hejna, M. et al., “Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial”, European Journal of Cancer 37(16), pp. 1994-2002, Nov. 2001.
Cao, S. et al., “5-Fluorouracil Prodrug: Role of Anabolic and Catabolic Pathway Modulation in Therapy of Colorectal Cancer”, Clinical Cancer Research, vol. 1, pp. 839-845, Aug. 1995.
Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9thEdition, 1996, pp. 125-1229.
Stein, J. H., Editor-in-Chief, Internal Medicine, 4th Edition Chapters 71 and 72, 1994.
Cao, S. et al., Clinical Cancer Research, vol. 1, “5-Fluorouracil Prodrug: Role of Anabolic and Catabolic Pathway Modulation in Therapy of Colorectal Cancer,” pp. 839-845, Aug. 1995.
Childress, J. et al., American Journal of Clinical Oncology, vol. 26, No. 5, “Cutaneous Hand and Foot Toxicity Associated with Cancer Chemotherapy,” pp. 435-436, Oct. 2003.
Chua, D. et al., Proc Am Soc Clin Oncol vol. 22, “Efficacy of capecitabine monotherapy in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platiunum-based chemotherapy,” p. 511, 2003.
Ehrianger M. et al., Dermatologica, vol. 140, Suppl. I. “Cutaneous Absorption and Urinary Excretion of 6-14C-5-Fluorouracil Ointment Applicated in an Ointment to Healthy and Diseased Human Skin,” pp. 129-136, 1970.
Elasmar, et al., Jpn J Clin Oncol 2001; 31(4)172-174. Case Report: Hand-Foot Syndrome Induced by Oral Fluoropyrimidine S-1.
Findlay M. et al., Annals of Oncology 7:47-53. “Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients in protracted venous Infusion with or without interferon-α, ” pp. 111-117, 1996.
Fischel J-L., et al., Proceedings of the American Association for Cancer Research, vol. 45. “Experimental arguments for a better understanding of hand-foot syndrome under capecitabine,” p. 487, Mar. 2004 (Abstract #2119).
Fujii S. et al., Gann, 70. “Effect of Coadministration of Uracil or Cytosine on the Anti-Tumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents,” pp. 209-214, Apr. 1979.
Fukushima S, et al., Cancer Research 52, “Carcinogenicity of Uracil, a Nongenotoxic Chemical, in Rats and Mice and I Rationale,” pp. 188-193, Apr. 1, 1992.
Gallo R, et al., The Journal of Clinical Investigation, vol. 48, “The Enzymatic Mechanisms for Deoxythymidine Synthesis in Human Leukocites,” pp. 82-93, 1969.
Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9thEdition, pp. 1225-1229, 1996.
Hageboutrous, J.M. et al., Clinical Cancer Research, vol. 5. “Life threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil,” pp. 2006-2011, 1999.
Hartmann, H.R., et al., Med. Oncol. & Tumor Pharmacother, vol. 3 No. 2, “Modulation of the Effects of Fluoropyrimidines on Toxicity and Tumor Inhibition in Rodents by Uridine and Thymidine,” pp. 111-118, Apr. 25, 1986.
Hatfield D., et al., The Journal of Biological Chemistry. “Synthesis of (3-Ribosyluric Acid) 5′-Phosphate and (3-Ribosylxanthine) 5′-Phosphate by a Pyrimidine Ribonucleotide Pyrophosphorylase of Beef Erythocytes,” pp. 60-66, Aug. 1964.
Paulo Hoff, Investigational New Drugs 18. “The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL ™) and S-1:a review of their clinical development and therapeutic potential,” pp. 153-163, 2000.
Ichikawa W., et al., Gastrointestinal Cancer, “Polymorphisms of orotate phosphoribosyl transferase (OPRT) gene and thymidylate synthase tandem repeat (TSTR) predict adverse events (AE) in colorectal cancer (CRC) patients treated with 5-fluorouracil (FU) pluis leucovorin (LV),”p. 1063, 2003.
Ichikawa, W., et al., British Journal of Cancer (2003) 89. “Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimdine-based chemotherapy for metastatic colorectal cancer,” 2003 Cancer Research UK.
Ikenaka K., et al., Gann, 70. “Effect of Uracil on Metabolism of 5-Fluorouracil in Vitro,” pp. 353-359, Jun. 1979.
Johnson M., et al., Clinical Cancer Research, vol. 5, “Life-Threatening Toxicity in a Dihydropyrimidine Dehydrogenase-Deficient Patient after Treatment with Topical 5-Fluorouracil,” pp. 141-146, Aug. 1999.
Kawaguchi Y., et al., Gann, 71. “Studies on the Metabolism of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Uracil Co-Administered Orally to Tumor-Bearing Rats,” pp. 889-899, Dec. 1980.
Largillier R., et al., “Prospective Analysis of Dihydropyrimidine Dehydrogenase (Dpd) Activity for Predicting Capecitabine-Related Toxicities in Metastatic Breast Cancer Patients,” p. 39, (Roster Abstract).
Leo S., et al., Journal of Chemotherapy, vol. 6, n. 6 “Dermatological Toxicity from Chemotherapy Containing 5-Fluorouracil,” pp. 2-5, 1994.
Levy S., et al. Clinical Therapeutics/vol. 23, No. 6 “A Pharmacokinetic Evaluation of 0.5% and 5% Fluorouracil Topical Cream in Patients with Actinic Keratosis,” pp. 908-920, 2001.
Luccioni, et al., Int. J. Cancer: 58, “Pyrimidine Nucleotide Metabolism in Human Colon Carcinomas: Comparison of Normal Tissues Primary Tumors and Xenografts,” pp. 32-37, 1994.
Mackean M., et al., Journal of Clinical Oncology, vol. 16, No. 9, “Phase I and Pharmacologic Study of Intermittent Twice-Daily Oral Therapy with Capecitabine in Patients with Advanced and/or Metastatic Cancer,” pp. 2977-2985, Sep. 1998.
Maehara Y., et al., Oncology, vol. 11, No. 9, “Scientific Basis for the Combination of Tegafur with Uracil,” pp. 14-21, Supplement No. 10.
Malet-Martino M., et al., The Oncologist 2002, “Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capectiabine, UFT, S-1): A Review,” pp. 288-323.
Niedzwicki J., et al., Biochemical Pharmacology, vol. 32, No. 3, “Structure-Activity Relationship of Ligands of the Pyrimidine Nucleoside Phosphorylases,” pp. 399-415, 1983.
Niedzwicki J., et al., Biochemical Pharmacology, vol. 33, No. 15, “Structure-Activity Relationship of Pyrimidine Base Analogs as Ligands of Orotate Phosphoribosyltransferase,” pp. 2383-2395, 1984.
Naguib, et al., Cancer Research 45, “Enzymes of Uracil Catabolism in Normal and Neoplastic Human Tissues,” pp. 5405-5412, Nov. 1985.
Powis, G., International Encyclopedia of Pharmacology and Therapeutics, Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents, pp 42-50, 1994.
Samid, D., Roche Laboratories Inc., “Important Information About Xeloda (capecitabine) Tablets,” Aug. 2003.
Sawada N., et al., Clinical Cancer Research, vol. 4, “Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/Taxotere in Human Cancer Xenografts,” pp. 1013-1019, Apr. 1998.
Schilsky R.L., et al., Food and Drug Administration Center for Drug Evaluation and Research, “Sixty-Third Meeting of the Oncologic Drug Advisory Committee”, Sep. 16, 1999.
Senff H., et al., British Journal of Dermatology 118, “Topical 5-Fulorouracil Solution in the Treatment of Warts—Clinical Experience and Percutaneous Absorption,” pp. 409-414, 1988.
Sludden J., et al., Pharmacology, “Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse,”
Dechert LLP
Jones Dwayne
LandOfFree
Methods, compositions, and kits for organ protection during... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods, compositions, and kits for organ protection during..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods, compositions, and kits for organ protection during... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3692261